Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-2118PMID 29196297PMCID PMC5844814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

  2017cited by this paper
• Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

  2017cited by this paper
• Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition

  2017cited by this paper
• Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]

  2017cited by this paper
• PIM kinases as therapeutic targets against advanced melanoma

  2016cited by this paper
• Suppression of B-Raf(V600E) cancers by MAPK hyper-activation

  2016cited by this paper
• Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF

  2016cited by this paper
• Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1

  2015cited by this paper
• Aspirin for the primary prevention of skin cancer: A meta-analysis

  2015cited by this paper
• Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.

  2015cited by this paper
• Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

  2015cited by this paper
• Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants

  2015cited by this paper
• Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma

  2015cited by this paper
• Improving Prospects for Targeting RAS.

  2015cited by this paper
• The double-edged sword of AMPK signaling in cancer and its therapeutic implications

  2015cited by this paper
• Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

  2015cited by this paper
• Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines

  2015influential reference
• Therapeutic resistance: Paradox breaking

  2015cited by this paper
• Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study

  2014cited by this paper
• Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

  2014cited by this paper
• Beyond BRAF: where next for melanoma therapy?

  2014cited by this paper
• Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics*

  2014influential reference
• Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

  2014cited by this paper
• Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells

  2014cited by this paper
• Aspirin and Other NSAIDs as Chemoprevention Agents in Melanoma

  2014cited by this paper
• Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma

  2013cited by this paper
• Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

  2013cited by this paper
• Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

  2013cited by this paper
• NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

  2013cited by this paper
• Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma

  2013cited by this paper
• MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

  2013cited by this paper
• Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

  2013cited by this paper
• The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase

  2012influential reference
• A comprehensive survey of Ras mutations in cancer.

  2012cited by this paper
• Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).

  2012cited by this paper
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012cited by this paper
• DUSPs, to MAP kinases and beyond

  2012cited by this paper
• Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study

  2012cited by this paper
• Targeting the RAS pathway in melanoma.

  2012cited by this paper
• Aspirin and the prevention of colorectal cancer.

  2012cited by this paper
• A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation

  2012cited by this paper
• Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

  2011cited by this paper
• Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1

  2011cited by this paper
• Detecting mycoplasma contamination in cell cultures by polymerase chain reaction.

  2011cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010influential reference
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• Tumor and Stem Cell Biology Cancer Research A Mouse Model of Melanoma Driven by Oncogenic KRAS

  2010cited by this paper
• A mouse model of melanoma driven by oncogenic KRAS.

  2010cited by this paper
• Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.

  2010cited by this paper
• Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF.

  2010cited by this paper
• Sorafenib: a clinical and pharmacologic review

  2010cited by this paper
• AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival.

  2010cited by this paper
• Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAFV600E

  2009cited by this paper
• Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

  2009cited by this paper
• Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

  2009cited by this paper
• Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.

  2009cited by this paper
• Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.

  2008influential reference
• Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets

  2007cited by this paper
• Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.

  2007cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox‐ independent mechanism

  2006cited by this paper
• Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.

  2006cited by this paper
• Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

  2006cited by this paper
• Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

  2006cited by this paper
• The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.

  2006influential reference
• Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).

  2005cited by this paper
• Detecting Mycoplasma contamination in cell cultures by polymerase chain reaction.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Aspirin and the prevention of colorectal cancer.

  2003cited by this paper
• The mechanism of action of aspirin.

  2003cited by this paper
• Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines

  2002cited by this paper
• Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.

  1995cited by this paper
• Modes of action of aspirin-like drugs.

  1985cited by this paper
• Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

  1984cited by this paper

• Targeting the MDK/c‐Myc complex to overcome temozolomide resistance in glioma

  2025cites this paper
• Acetylsalicylic acid and cancer: updates on the new potential of a nature-inspired drug

  2025cites this paper
• Research progress on aging mechanism and drugs and the role of stem cells in anti-aging process.

  2023cites this paper
• Aspirin Synergizes with Regorafenib to Reduce Growth of Colorectal Cancer

  2022cites this paper
• IQ Motif Containing GTPase Activating Proteins (IQGAPs), A-Kinase Anchoring Proteins (AKAPs) and Kinase Suppressor of Ras Proteins (KSRs) in Scaffolding Oncogenic Pathways and Their Therapeutic Potential

  2022cites this paper
• Blockade of AMPK-Mediated cAMP–PKA–CREB/ATF1 Signaling Synergizes with Aspirin to Inhibit Hepatocellular Carcinoma

  2021cites this paper
• In Vitro Effects of Selective COX and LOX Inhibitors and Their Combinations with Antineoplastic Drugs in the Mouse Melanoma Cell Line B16F10

  2021cites this paper
• Non‐Steroidal Anti‐Inflammatory Drugs (NSAIDs) sensitize melanoma cells to MEK inhibition and inhibit metastasis and relapse by inducing degradation of AXL

  2021influential citation
• NSAIDs: Old Acquaintance in the Pipeline for Cancer Treatment and Prevention─Structural Modulation, Mechanisms of Action, and Bright Future.

  2021cites this paper
• Acetylsalicylic acid and salicylic acid present anticancer properties against melanoma by promoting nitric oxide-dependent endoplasmic reticulum stress and apoptosis

  2020cites this paper
• Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid Lipid Microparticles

  2020cites this paper
• Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine

  2020cites this paper
• Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies

  2020cites this paper
• MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities

  2019cites this paper
• ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma

  2019cites this paper
• Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer

  2019cites this paper
• Complex roles of the old drug aspirin in cancer chemoprevention and therapy

  2018cites this paper
• Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.

  2018cites this paper